Wall Street analysts predict that Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) will announce ($0.82) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have made estimates for Eiger Biopharmaceuticals’ earnings. The lowest EPS estimate is ($1.13) and the highest is ($0.60). Eiger Biopharmaceuticals reported earnings of ($1.10) per share during the same quarter last year, which indicates a positive year over year growth rate of 25.5%. The firm is scheduled to report its next earnings report on Thursday, November 8th.

On average, analysts expect that Eiger Biopharmaceuticals will report full-year earnings of ($3.19) per share for the current financial year, with EPS estimates ranging from ($4.22) to ($2.71). For the next financial year, analysts forecast that the firm will report earnings of ($3.24) per share, with EPS estimates ranging from ($3.82) to ($2.60). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side analysts that follow Eiger Biopharmaceuticals.

Eiger Biopharmaceuticals (NASDAQ:EIGR) last announced its quarterly earnings data on Friday, August 10th. The biotechnology company reported ($0.82) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.82).

A number of equities research analysts have commented on the company. Piper Jaffray Companies raised their price objective on Eiger Biopharmaceuticals to $28.00 and gave the stock an “overweight” rating in a research report on Friday, May 18th. Oppenheimer set a $26.00 price objective on Eiger Biopharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, May 17th. BTIG Research raised their price objective on Eiger Biopharmaceuticals from $23.00 to $39.00 and gave the stock a “buy” rating in a research report on Thursday, May 17th. Zacks Investment Research lowered Eiger Biopharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, May 22nd. Finally, ValuEngine upgraded Eiger Biopharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Thursday, May 17th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $30.75.

Several institutional investors and hedge funds have recently bought and sold shares of EIGR. Jennison Associates LLC raised its stake in shares of Eiger Biopharmaceuticals by 93.3% during the 2nd quarter. Jennison Associates LLC now owns 1,256,501 shares of the biotechnology company’s stock worth $15,329,000 after purchasing an additional 606,361 shares in the last quarter. GMT Capital Corp purchased a new stake in shares of Eiger Biopharmaceuticals during the 2nd quarter worth about $3,459,000. BlackRock Inc. raised its stake in shares of Eiger Biopharmaceuticals by 171.0% during the 2nd quarter. BlackRock Inc. now owns 219,278 shares of the biotechnology company’s stock worth $2,675,000 after purchasing an additional 138,366 shares in the last quarter. Millennium Management LLC purchased a new stake in shares of Eiger Biopharmaceuticals during the 2nd quarter worth about $871,000. Finally, Renaissance Technologies LLC raised its stake in shares of Eiger Biopharmaceuticals by 40.4% during the 2nd quarter. Renaissance Technologies LLC now owns 230,229 shares of the biotechnology company’s stock worth $2,809,000 after purchasing an additional 66,200 shares in the last quarter. 71.61% of the stock is owned by institutional investors.

Shares of NASDAQ EIGR opened at $11.85 on Wednesday. Eiger Biopharmaceuticals has a one year low of $7.46 and a one year high of $18.00. The stock has a market cap of $101.18 million, a price-to-earnings ratio of -2.44 and a beta of 1.68. The company has a debt-to-equity ratio of 0.81, a current ratio of 4.51 and a quick ratio of 4.51.

About Eiger Biopharmaceuticals

Eiger BioPharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare diseases in the United States and internationally. The company's lead program is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trial for treating hepatitis delta virus (HDV) infection.

Featured Story: Closed-End Mutual Funds

Get a free copy of the Zacks research report on Eiger Biopharmaceuticals (EIGR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Eiger Biopharmaceuticals (NASDAQ:EIGR)

Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.